Use of anastrozole for breast cancer prevention (IBIS-II): long term results of a randomized controlled trial. Lancet 2020; 395: 117-122
Published: 5th March 2020
Authors: Cuzik J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE et al.
After median follow-up of 131 months in this study that included 3864 women, five years of anastrozole reduced the risk of breast cancer: hazard ratio 0.51, 95 per cent confidence interval 0.39 to 0.66, P<0.0001. The reduction was greatest for the first five years, but still significant thereafter (0.64, 0.45 to 0.91, P=0.014).Pubmed Link
You may also be interested in
External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node negative breast cancer (RAPID): a randomized controlled trial. Lancet 2019; 394: 2165-2172
Authors: Whelan TJ, Julian JA, Berrang TS, Kim D-H, Germain I, Nichol AM et al.
Long term results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomized, phase 3, equivalence trial. Lancet 2019; 394: 2155-2164
Authors: Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA et al.
Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor–positive early breast cancer: PALLET trial. J Clin Oncol 2019; 37: 178-189.
Authors: Johnston S, Puhalla S, Wheatley D, Ring A, Barry P, Holcombe C et al.
Adjuvant letrozole and tamoxifen alone or sequentially for postmenopausal women with hormone receptor–positive breast cancer: long-term follow-up of the BIG 1-98 Trial. J Clin Oncol 2019; 37: 105-114.
Authors: Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen M-B, Ejlertson B, de Azambuja E et al.
Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.
Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.
Six months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial. Lancet 2019; 393: 2591-2598.
Authors: Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T et al.
Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH Phase 3 randomized clinical trial. JAMA Oncol 2019; 5:e190339.
Authors: Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC et al.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019; 393: 1440-1452.
Authors: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 2019; 380: 617-628.
Authors: Von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al.
Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol 2018; 36: 3126-3133.
Authors: Bardia A, Parton M, Kummel S, Estevez LG, Huang C-S, Cortes J et al.
Double-blind phase III trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node–positive and high-risk lymph node–negative breast cancer (E5103). J Clin Oncol 2018; 36: 2621-2629.
Authors: Miller KD, O’Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA et al.
Effects of celecoxib and low-dose aspirin on outcomes in adjuvant aromatase inhibitor–treated patients: CCTG MA.27. J Natl Cancer Inst 2018; 110: 1003–1008.
Authors: Strasser-Weippl K, Higgins MJ, Chapman J-AW, Ingle JN, Sledge GW, Budd GT et al.